- Phase I/II combination study of tifcemalimab with toripalimab in patients with refractory extensive stage small cell lung cancer (ES-SCLC)Cheng, Ying; Wang, Jie; Yu, Yan; Wang, Qiming; Yang, Runxiang; Lv, Dongqing; Xia, Bing; Yi, Tienan; Li, Chong; Wang, Xicheng; Zhang, Wei; Han, Liang; Liu, Xiaoqing; Shen, Minjie; Xu, Jing; Xue, Peng; Wang, WeihuaAnnual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Chicago, IL, 2023-06-02 To 2023-06-06.
- Perioperative toripalimab plus platinum-doublet chemotherapy vs chemotherapy in resectable stage II/III non-small cell lung cancer (NSCLC): Interim event-free survival (EFS) analysis of the phase III NEOTORCH studyLu, Shun; Wu, Lin; Zhang, Wei; Zhang, Peng; Wang, Wenxiang; Fang, Wentao; Xing, Wenqun; Chen, Qixun; Mei, Jiandong; Yang, Lin; Tan, Lijie; Sun, Xiaohong; Xu, Shidong; Hu, Xiaohua; Yu, Guohua; Yu, Dongliang; Shan, Jinlu; Yang, Nong; Chen, Yuping; Tian, HuiAnnual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Chicago, IL, 2023-06-02 To 2023-06-06.被引 6
- Perioperative toripalimab plus platinum-doublet chemotherapy vs chemotherapy in resectable stage II/III non-small cell lung cancer (NSCLC): Interim event-free survival (EFS) analysis of the phase III Neotorch study.Lu, Shun; Wu, Lin; Zhang, Wei; Zhang, Peng; Wang, Wenxiang; Fang, Wentao; Xing, Wenqun; Chen, Qixun; Mei, Jiandong; Yang, Lin; Tan, Lijie; Sun, Xiaohong; Xu, Shidong; Hu, Xiaohua; Yu, Guohua; Yu, Dongliang; Shan, Jinlu; Yang, Nong; Chen, Yuping; Tian, HuiAnnual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 2023-11 To 2023-11.被引 29
会议论文
EXTENTORCH: A randomized, phase III trial of toripalimab versus placebo, in combination with chemotherapy as a first-line therapy for patients with extensive stage small cell lung cancer (ES-SCLC)
21阅读
